. Author manuscript; available in PMC: 2021 Aug 11.

Published in final edited form as: Mult Scler. 2020 Oct 15;27(9):1384–1390. doi: 10.1177/1352458520964409

Table 1:

Baseline patient characteristics, modified intent to treat population (n=244)

	ibudilast	placebo	p-value
N (patients)	121	123
Age (mean years +/− SD)	54.7314 ± 7.7063	56.8909 ± 6.4984	0.02
Disease duration (median, range)	11 (0 – 41)	9 (0 – 36)	0.77
Primary Progressive (n, %)	63 (52.07%)	64 (52.03%)	0.9958
EDSS (median, range)	6 (2.5–6.5)	6 (3 – 6.5)	0.45
2.5% LCLA (mean number correct +/− SD)	29.6750 ± 12.2063^†	27.2213 ± 12.6357^†	0.13^†
pRNFL (mean^* +/− SD)	83.3944 ± 10.5055^†	81.0000 ± 13.1451^†	0.12^†
Macular Volume (mean +/− SD)(Spectralis sites)	8.2572 ± 0.4601^†	8.1178 ± 0.4580	0.24
Macular Volume (mean +/− SD)(Cirrus sites)	9.6961 ± 0.5366	9.5879 ± 0.5760^†	0.19
GCIP (mean +/− SD) (Cirrus sites only)	71.6861 ± 8.9790	68.8861 ± 9.7125^†	0.05

mean of the left and right eye measures. When measures from both eyes were unavailable, the value for the one available eye was used.

^†

denotes unavailable data as follows: 2.5% LCLA, 1 ibudilast subject and 1 placebo subject, pRNFL, 5 ibudilast subjects, 4 placebo subjects; Macular Volume (Spectralis sites), 1 ibudilast subject; Macular Volume (Cirrus sites), 2 placebo subjects; GCIP, 3 placebo subjects.